MedTrace Logo

Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

NCT03613753 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2020-02-05

No results posted yet for this study

Summary

This randomized phase II study compare survival outcomes and toxicity of two chemotherapy regimens (irinotecan plus lobaplatin or irinotecan) for the second-line treatment of recurrent small-cell lung cancer.

Conditions

  • Small-cell Lung Cancer

Interventions

DRUG

irinotecan plus lobaplatin

irinotecan plus lobaplatin chemotherapy

DRUG

irinotecan

irinotecan chemotherapy alone

Sponsors & Collaborators

  • ShengFa Su

    lead OTHER

Principal Investigators

  • ShengFa Su, PhD,MD · The Affiliated Hospital Of Guizhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2020-06-01
Completion
2021-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03613753 on ClinicalTrials.gov